Also known as: Kepivance

FDA-approved for oral mucositis (Kepivance). FGFR2b-mediated follicle keratinocyte proliferation is well-characterized, but no clinical trials exist for hair loss specifically.

📖 Read the full KGF / Palifermin research overview →

Evidence Tier: Tier 1 — Approved Drug · Peptidings Verdict: Strong Foundation